Replies to Post #31516 onEnzolytics Inc (ENZC)

Replies to #31516 on Enzolytics Inc (ENZC)

cjstocksup

10/10/20 2:32 PM

#31518 RE: trader53 #31516

I agree. The next leg up should be .025 to .05.

ENZC - Targets $0.025 / $0.035

Truenorth2016

10/10/20 3:29 PM

#31535 RE: trader53 #31516

Uh Oh, Trader53 Back With His Near-term Targets!!! Getting Ready for Big Week Next Week!!!

cjstocksup

10/10/20 3:29 PM

#31537 RE: trader53 #31516

ENZC and BioClonetics: A Perfect Merger
Alex Carlson Alex Carlson

President Trump’s hospitalization for COVID-19 has shed the spotlight on the most important aspect in the treatment of the coronavirus – monoclonal antibodies. Dr. Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases (NIAID), is focused on looking at antivirals that have treated other infectious diseases like HIV to treat COVID-19. Two companies at the forefront of HIV therapeutics are ENZC and BioClonetics, which are set to merge.

In this video, Dr. Fauci lays out the importance of monoclonal antibodies in the treatment of COVID-19.

Trump’s Treatment
In analyzing the treatment of President Trump, the Doctors at Walter Reed Medical Center threw everything, but the kitchen sink at the coronavirus. On 2 October, the White House announced President Donald Trump received an experimental antibody treatment after a test revealed he’s infected with SARS-CoV-2. Later, the president’s medical team confirmed he had started a course of remdesivir, an antiviral drug shown to modestly help hospitalized COVID-19 patients. Two days later, on 4 October, the team revealed Trump had been given a steroid normally reserved for severe COVID-19 cases.

The statement released on 2 October by the president’s physician said that in addition to the antibodies, Trump “has been taking zinc, vitamin D, famotidine, melatonin and a daily aspirin.”

What people are failing to realize is that it is uncertain if the treatment(s) given to President Trump will work, and if they do, which one (s) worked. This is why we don’t have a vaccine or an approved treatment from the FDA yet. More testing and funding is needed.

The Importance Of HIV Research
Dr. Fauci is well-known for his contributions to HIV research. He understands the science and the disease perhaps as much an anyone. One company at the heart of HIV research and one which Dr. Fauci is familiar with is BioClonetics Immunotherapeutics, a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for produce fully human monoclonal antibodies may be used to produce therapeutics treatments for name infectious diseases including the Coronavirus.

Because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, BioClonetics has been asked by the National Science Foundation (NSF) to submit a funding application for the development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health (NIH).

Pepsin Enzyme
In addition to the antibody treatment, President Trump was given famotidine. Famotidine has been suggested to be a treatment for COVID-19, but it’s also a popular heartburn remedy, sold widely under the name Pepcid.

This is where ENZC comes in to play. Enzolytics’ flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.

The Perfect Merger With ENZC
The reason that the merger between ENZC and BioClonetics makes perfect sense is that BioClonetics Clone 3 recombinant mAbs will be combined with the Enzolytics’ flagship compound ITV-1, a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.

IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal, and hematological side effects seen in the antiretrovirals in use today. IPF has been shown to not be subject to viral resistance and is cost-effective. Charles Cotropia, CEO of BioClonetics said:

“Our proprietary methodology may also be applied to produce monoclonal antibodies against other infectious diseases and the invitation by the National Science Foundation (NSF) to apply for funding to further BioClonetics efforts to develop anti-SARS-Cov-2 monoclonal antibodies using our proprietary technology is an exciting development for BioClonetics. We have previously produced monoclonal antibodies against HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. We look forward to discovering how ENZC’s ITV-1 treatment can be used with our monoclonal antibody platform to synergistically improve our such antibodies for treating HIV.”

The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates.

Thereafter, additional PBMC based in-vitro neutralization studies will be conducted with the BioClonetics Clone 3 recombinant antibodies in combination with the Enzolytics ITV-1 peptide. Based on the results, the best combination will be tested in primate studies at the California National Primate Research Center University of California, Davis, California.

The proposed merger anticipated in the non-binding LOI will result in Charles Cotropia being appointed as CEO of the merged entity and Harry Zhabilov and Joseph Cotropia, MD, being appointed as co-CSO. Gaurav Chandra, MD, will serve as COO of the merged entity.

ENZC Bottom Line
The ENZC and BioClonetics merger is a game-changer for HIV/COVID-19 treatment. By combining the therapeutics produced by both companies, we believe an effective treatment will finally be available. The next steps we are watching for are 1. the merger closing and 2. NIH funding. We get both and shares of ENZC will go parabolic.

https://insiderfinancial.com/enzc-and-bioclonetics-a-perfect-merger/180505/amp/

trader53

10/11/20 2:58 AM

#31691 RE: trader53 #31516

ENZC - Targets $0.025 / $0.035

I'll Alert you of stocks to Buy,
before the Run happens !

________________________________________________________________

ENZC Security Details
Share Structure
Market Value1...........$38,287,121 a/o Oct 09, 2020
Authorized Shares...3,000,000,000 a/o Sep 30, 2020
Outstanding Shares..2,438,670,097 a/o Sep 30, 2020
Restricted..............767,839,585 a/o Sep 30, 2020
Unrestricted..........1,670,830,512 a/o Sep 30, 2020
Held at DTC...........1,271,629,924 a/o Sep 30, 2020
Float.....................Not Available
Par Value 0.001

https://www.otcmarkets.com/stock/ENZC/security

________________________________________________________________

How Targets are Calculated

Fibonacci Numbers and Retrace Targets: Explained

________________________________________________________________

Fibonacci Numbers

http://www.stockta.com/cgi-bin/school.pl?page=fib

Fibonacci Retracements

* Golden 61.8% Retracements

* Moderate 38.2% Retracements

* Common 38.2% Retracements

Fibonacci Retracements

http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:fibonacci_retracemen

________________________________________________________________

Fibonacci Numbers
are commonly used in Technical Analysis
with or without a knowledge of Elliot Wave Analysis
to determine potential support, resistance,
and price objectives.

The most popular Fibonacci Retracements are
61.8% and 38.2%

61.8% retracements
imply a new trend is establishing itself.

38.2% retracements
usually imply that the prior trend will continue

38.2% retracements
are considered natural retracements in a healthy trend.

Fibonacci Retracements
can be applied after a decline
to forecast the length of a counter-trend bounce.

________________________________________________________________

The 50% retracement is not based on a Fibonacci number.
Instead, this number stems from Dow Theory's assertion
that the Averages often retrace half their prior move.

50% retracement
implies indecision.

________________________________________________________________